Stock data
| Market cap. | £35.4m |
| Last close | 400.00p |
| High / Low (52 weeks) | 422.5p / 352.5p |
| Stock market listing | AIM |
| Forecast net cash (£m) | 2.6 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | (1.23) | 0.63 | 11.11 |
| Relative * | 3.62 | 8.89 | 22.11 |
* % Relative to local index
Other companies covered in sector
| Y/E Jun | Revenue (£m) | EBITDA (£m) | PBT (£m) | EPS (p) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2010A | 5.7 | 0.5 | 0.4 | 3.8 | 105.3 | N/A |
| 2011A | 5.8 | (0.4) | (0.6) | (7.0) | N/A | N/A |
| 2012E | 5.3 | (1.0) | (1.1) | (14.1) | N/A | N/A |
| 2013E | 5.6 | (1.0) | (1.1) | (13.9) | N/A | N/A |
Last updated on 17/04/2012
Latest research
Deals urgently needed
Update | Pharmaceutical & Healthcare | 31/03/2011
A steady platform
Update | Pharmaceutical & Healthcare | 16/03/2010
Leads and profits
Update | Pharmaceutical & Healthcare | 04/03/2009
Performance on track
Update | Pharmaceutical & Healthcare | 08/10/2008
Cancer stem cells
Review | Pharmaceutical & Healthcare | 01/08/2008
Strong first half growth
Update | Pharmaceutical & Healthcare | 28/02/2008
Hairy stories
Outlook | Pharmaceutical & Healthcare | 08/02/2008
Growth biomarker
Update | Pharmaceutical & Healthcare | 21/11/2007
Business cloning
Quarterly Update - Trading update | Pharmaceutical & Healthcare | 10/10/2007
Investment summary
Epistem reported H112 sales of £3.1m. The PBT loss (after £257k of capitalised R&D) was £536k. There was a £145k tax credit gain. A late 2011 funding boosted cash by £2.8m to £5.3m at the year end. Divisionally, CRO services were flat at £1.4m helped by increased US biodefense work. Biomarker services grew to £1.7m due to Sanofi buying c £1m of genetic analysis tests for its R&D projects; this level may not be sustained into H2. Other sales were of GenDrive (£0.3m, c 60 units); other hair test projects were flat at £0.4m.
Last updated on 23/04/2012
Industry outlook
Epistem believes Genedrive (a DNA-based diagnostic system for a point-of-care use) will change the shape of the DNA diagnostics. The latest data on its TB test showed a respectable 90% sensitivity (true cases found) but a weak, 80%, specificity (false positive rate) mean this test is mainly useful to confirm a probable diagnosis or test drug resistance (no data); not for 'wellness' screening. The TB market seems a good one as other tests are unreliable or expensive.
Last updated on 23/04/2012
Key management
| David Evans, Chairman |
| Matthew Walls, CEO |
| John Rylands, FD |
Company address
| 48 Grafton Street Manchester M13 9XX United Kingdom +44 (0) 161 606 7258 View website |
